Humulin Nph (Insulin Human (Rdna))

Humulin Nph is prescribed as part of a comprehensive diabetes treatment plan to provide basal insulin support.

• Control fasting plasma glucose in adults with type 1 diabetes mellitus.
• Maintain basal insulin levels in adults with type 2 diabetes mellitus.
• Adjunct to rapid‑acting insulin analogues for mealtime glucose management.
• Used when a longer‑acting insulin profile is required to reduce dosing frequency.
• Integrated into insulin pump therapy only under specialist supervision.

• Humulin Nph contains recombinant human insulin that binds to insulin receptors on muscle, adipose and hepatic cells. Receptor activation triggers autophosphorylation and downstream signaling through the PI3‑K/Akt pathway, promoting translocation of GLUT‑4 transporters to the cell surface and increasing glucose uptake. In the liver, it suppresses gluconeogenesis and glycogenolysis, thereby lowering circulating glucose and regulating carbohydrate, fat and protein metabolism.

Adverse reactions to Humulin Nph may vary in frequency and severity.

Common

• Mild hypoglycemia, especially if meals are delayed or carbohydrate intake is insufficient.
• Injection site reactions such as redness, swelling, or itching.
• Weight gain associated with improved glycemic control.
• Transient lipodystrophy at the injection site.

Serious

• Severe hypoglycemia leading to loss of consciousness or seizures.
• Allergic reactions including urticaria, angioedema, or anaphylaxis.
• Insulin edema causing peripheral swelling.

Before initiating Humulin Nph, clinicians should evaluate patient-specific factors and monitor for potential risks.

• Assess renal and hepatic function, as impairment may alter insulin clearance.
• Review history of hypoglycemia unawareness or recurrent severe episodes.
• Consider pregnancy status; insulin requirements may change during gestation.
• Avoid use in patients with known hypersensitivity to recombinant human insulin or protamine.
• Educate patients on proper injection technique to reduce lipodystrophy.
• Monitor weight and signs of fluid retention during therapy.
• Adjust dose when initiating or discontinuing concomitant glucocorticoids or beta‑blockers.

Humulin Nph can interact with other medicines, affecting glucose control or insulin action.

Avoid

• Concurrent use with other insulin products without dose adjustment may cause severe hypoglycemia.
• Combination with sulfonylureas or meglitinides increases risk of hypoglycemia.
• Co‑administration with high‑dose corticosteroids may reduce insulin effectiveness.

Use with caution

• Beta‑blockers may mask hypoglycemia symptoms; monitor blood glucose closely.
• ACE inhibitors and ARBs can potentiate insulin’s glucose‑lowering effect.
• Thiazide diuretics may raise blood glucose, requiring dose reassessment.
• Alcohol intake can potentiate insulin’s effect and precipitate hypoglycemia.